このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Inhibikase Therapeutics 将来の成長

Future 基準チェック /06

Inhibikase Therapeuticsは、32.1%と76.8%でそれぞれ年率32.1%で利益と収益が成長すると予測される一方、EPSはgrowで51.3%年率。

主要情報

32.1%

収益成長率

51.3%

EPS成長率

Biotechs 収益成長	24.2%
収益成長率	76.8%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	21 May 2024

今後の成長に関する最新情報

Recent updates

Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation

Apr 06

Inhibikase Therapeutics prices stock offering at $3

Jun 16

業績と収益の成長予測

NasdaqCM:IKT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	9	-25	-28	-21	2
12/31/2025	N/A	-26	-32	-20	2
12/31/2024	N/A	-19	-24	-18	2
3/31/2024	0	-19	-16	-16	N/A
12/31/2023	0	-19	-18	-18	N/A
9/30/2023	0	-19	-18	-18	N/A
6/30/2023	0	-19	-20	-20	N/A
3/31/2023	0	-18	-20	-19	N/A
12/31/2022	0	-18	-18	-17	N/A
9/30/2022	0	-19	-18	-18	N/A
6/30/2022	0	-19	-14	-14	N/A
3/31/2022	2	-17	-14	-14	N/A
12/31/2021	3	-15	-14	-14	N/A
9/30/2021	3	-11	-11	-11	N/A
6/30/2021	3	-7	-9	-9	N/A
3/31/2021	2	-5	-5	-5	N/A
12/31/2020	1	-3	-1	-1	N/A
9/30/2020	1	-2	0	0	N/A
6/30/2020	1	-3	0	0	N/A
3/31/2020	1	-5	0	0	N/A
12/31/2019	1	-6	0	0	N/A
9/30/2019	2	-7	1	1	N/A
3/31/2019	4	-4	0	0	N/A
12/31/2018	4	-2	1	1	N/A
9/30/2018	3	-1	0	0	N/A
3/31/2018	3	0	0	0	N/A
12/31/2017	2	0	N/A	0	N/A
12/31/2016	1	-1	N/A	0	N/A

アナリストによる今後の成長予測

収入対貯蓄率: IKT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: IKT今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: IKT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: IKT来年は収益がないと予測されています。

高い収益成長: IKT来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: IKTの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Inhibikase Therapeutics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 44%

Consensus revenue estimates increase by 178%, EPS downgraded

Recent updates

Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.8 million.

First quarter 2024 earnings released: US$0.73 loss per share (vs US$0.98 loss in 1Q 2023)

Inhibikase Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.

Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

New major risk - Market cap size

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Full year 2023 earnings: EPS misses analyst expectations

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.659255 million.

New major risk - Share price stability

Consensus revenue estimates increase by 44%

Inhibikase Therapeutics Announces Chief Financial Officer Changes, Effective End of the First Quarter of 2024

Inhibikase Therapeutics, Inc. Provides Update on Development Programs

Inhibikase Therapeutics, Inc. Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Third quarter 2023 earnings released: US$0.86 loss per share (vs US$1.07 loss in 3Q 2022)

Inhibikase Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment

Inhibikase Therapeutics, Inc. Announces Development of Novel Formulation of Rampsvodetinib

Consensus revenue estimates increase by 178%, EPS downgraded

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of Ikt-001Pro

New major risk - Financial position

Second quarter 2023 earnings released: US$1.11 loss per share (vs US$1.10 loss in 2Q 2022)

Inhibikase Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

Inhibikase Therapeutics Announces 1-For-6 Reverse Stock Split to Bring the Company into Compliance with Nasdaq's Minimum Bid Price Requirement

Inhibikase Therapeutics, Inc. Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

Inhibikase Therapeutics, Inc. Initiates Medical and Patient Awareness Campaign for Its Phase 2 '201' Trial Evaluating It-148009 in Parkinson's Disease

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.18 loss in 1Q 2022)

Inhibikase Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 23, 2023

Inhibikase Therapeutics, Inc. announced that it expects to receive $4.199512 million in funding

Inhibikase Therapeutics Announces Publication Demonstrating Potential for C-Abl as A Key Therapeutic Target in Parkinson's Disease and Related Disorders

Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?

Inhibikase Therapeutics, Inc. Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro

Inhibikase Therapeutics, Inc. Provides Update to FDA Clinical Hold of IkT-148009 Programs

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.18 loss in 3Q 2021)

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Inhibikase Therapeutics, Inc Announces FDA Clinical Hold on IkT-148009 Programs

High number of new and inexperienced directors

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. Announces Executive Changes

Inhibikase Therapeutics, Inc Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia

Inhibikase stock rises 12% on FDA nod to start study of IkT-001Pro for leukemia

Inhibikase Therapeutics, Inc. Doses First Patient in Its Phase 2a '201' Clinical Trial of IKT-148009 to Treat Parkinson's Disease

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2021)

Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M

Inhibikase Therapeutics, Inc. to Report Q2, 2022 Results on Aug 12, 2022

Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?

Inhibikase Therapeutics Receives a Letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Inhibikase Therapeutics, Inc. Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review

First quarter 2022 earnings released: US$0.18 loss per share (vs US$0.26 loss in 1Q 2021)

Inhibikase Therapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 24, 2022

Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation

Full year 2021 earnings released: US$0.81 loss per share (vs US$0.35 loss in FY 2020)

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.082 loss in 3Q 2020)

Inhibikase Therapeutics, Inc. Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy

Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.052 loss in 2Q 2020)

Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell Microcap Value Index

Inhibikase Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $45 million.

Inhibikase Therapeutics prices stock offering at $3

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.067 loss in 1Q 2020)

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.067 loss in 1Q 2020)

CEO, President & Director exercised options and sold US$71k worth of stock

Full year 2020 earnings released: US$0.35 loss per share (vs US$0.70 loss in FY 2019)

Inhibikase Therapeutics, Inc. Announces Update on Phase 1 Clinical Trial of IkT-148009

Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from NASDAQ Composite Index

Inhibikase Therapeutics, Inc. to Appoint C. Warren Olanow as Interim Chief Medical Officer

Inhibikase Therapeutics, Inc. has completed an IPO in the amount of $18 million.